Inhibiting Plasma Kallikrein for Hereditary Angioedema ProphylaxisAleena Banerji, Burt Adelman, Mark Davis‐Lorton et al.|New England Journal of Medicine|2017Cited by 171
Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World StudyJonathan A. Bernstein, Mark Weinstein, Stephen Betschel et al.|Advances in Therapy|2025Cited by 10